Skip to main content

Table 3 Effectiveness and safety of BI with or without metformin after 6 months - results of propensity score regressiona

From: Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China

Dependent variables

BI with metformin

BI without metformin

P value

The full population ( NĀ  = 12,358)

NĀ  = 6621

NĀ  = 5737

Ā 

Ā HbA1c control, % (95ā€‰% CI)

Ā Ā ā‰¤6.5ā€‰%

25.0 (20.9, 29.5)

22.1(18.4, 26.3)

0.0024

Ā Ā <7.0ā€‰%

39.9 (34.1, 45.0)

36.4 (31.7, 41.3)

0.0011

Ā HbA1c level (%), mean (95ā€‰% CI)

Ā Ā Mean level at v3

7.4 (7.3, 7.6)

7.5 (7.4, 7.6)

0.0302

Ā Ā Change from baseline

-1.8 (-1.9, -1.6)

-1.7 (-1.9, -1.5)

0.1839

Ā FPG control (<7.0 mmol), % (95ā€‰% CI)

36.0 (31.2, 41.0)

33.5 (28.9, 38.5)

0.0515

Ā FPG level (mmol/L), mean (95ā€‰% CI)b

Ā Ā Mean level at v3

8.3 (8.1, 8.5)

8.3 (8.1, 8.5)

0.6875

Ā Ā Change from baseline

-2.9 (-3.3, -2.5)

-3.0 (-3.3, -2.5)

0.5169

Ā Insulin dose (U/day/kg), mean (95ā€‰% CI)

Ā Ā Insulin dose at v3

0.33 (0.32, 0.33)

0.34 (0.33, 0.34)

<0.0001

Ā Ā Change from v1 to v3

0.064 (0.059, 0.060)

0.068 (0.063, 0.070)

0.0035

Ā Weight (kg), mean (95ā€‰% CI)

Ā Ā Mean level at v3

70.1 (69.3, 70.0)

70.3 (69.4, 71.2)

0.4862

Ā Ā Change from baseline

0.35 (0.11, 0.59)

0.37 (0.13, 0.62)

0.7223

Ā Hypoglycemia, % (95ā€‰% CI)

11.2 (9.1, 13.8)

10.4 (8.4, 12.8)

0.2965

The sub-population ( N = 8035)

N = 4269

N = 3799

Ā 

Ā HbA1c control, % (95ā€‰% CI)

Ā Ā ā‰¤6.5ā€‰%

30.1 (28.4, 31.8)

25.1 (23.4, 26.8)

0.0003

Ā Ā <7.0ā€‰%

47.9 (46.1, 49.7)

41.9 (39.9, 43.8)

0.0001

Ā HbA1c level (%), mean (95ā€‰% CI)

Ā Ā Mean level at v3

7.2 (7.2, 7.3)

7.3 (7.3, 7.4)

0.0009

Ā Ā Change from baseline

-2.0 (-2.1, -1.9)

-1.9 (-2.0, -1.9)

0.4175

Ā FPG control (<7.0 mmol), % (95ā€‰% CI)

49.6 (47.5, 51.8)

46.8 (44.5, 49.1)

0.1319

Ā FPG level (mmol/L), mean (95ā€‰% CI) c

Ā Ā Mean level at v3

7.5 (7.4, 7.6)

7.6 (7.5, 7.7)

0.2212

Ā Ā Change from baseline

-3.7 (-3.8, -3.5)

-3.7 (-3.9, -3.5)

0.8499

Ā Insulin dose (U/day/kg), mean (95ā€‰% CI)

Ā Ā Insulin dose at v3

0.21 (0.20, 0.21)

0.22 (0.21, 0.21)

<0.0001

Ā Ā Change from v1 to v3

0.033 (0.031, 0.035)

0.037 (0.035, 0.039)

0.0073

Ā Weight (kg), mean (95ā€‰% CI)

Ā Ā Mean level at v3

67.4 (67.0, 67.8)

67.7 (67.3, 68.1)

0.2965

Ā Ā Change from baseline

-0.12 (-0.22, -0.02)

0.15 (0.042, 0.24)

0.0013

Ā Hypoglycemia, % (95ā€‰% CI)

7.2 (6.3, 8.2)

6.9 (6.0, 8.0)

0.6892

  1. Abbreviations: v1 baseline, visit 1, v3 6-month, visit 3
  2. aIndependent variables include propensity score, process confounding factors and metformin group. Baseline covariates balanced by propensity score adjustments between two groups include regions, hospital level, gender, age, current residence, medical insurance (actual proportion of out of pocket), BMI, diabetes duration, OAD treatment duration, HbA1c level and FPG level at baseline, diabetes complication, number and types of OADs before BI therapy, BI types at BI therapy initiation. Process confounding factors controlled in the models include the number of OADs and total insulin dose (uncontrolled in the model when analyzed as the outcome) at visit 3, physical activity and diet consumption
  3. b4018 patients had missing data for FPG level with 2190 patients from BI with metformin group and 1828 patients from BI without metformin group
  4. c2440 patients had missing data for FPG level with 1306 patients from BI with metformin group and 1134 patients from BI without metformin group